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Here we describe a case of a methicillin-resistant coagulase-
negative staphylococci prosthetic valve endocarditis in a pa-
tient considered not eligible for valve replacement due to high 
perioperative mortality risk and who did not tolerate oral anti-
biotic treatment. Under these circumstances, intravenous long-
term chronic suppressive antibiotic therapy with dalbavancin, 
scheduling the doses using the serum bactericidal activity titers, 
proved to be safe and effective.
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Valve replacement and intravenous targeted antibiotics are the 
cornerstone of therapy of methicillin-resistant coagulase-negative 
staphylococci prosthetic valve endocarditis (MRCoNS PVE) [1]. 
However, occasionally patients refuse or are not eligible for valve 
replacement due to poor clinical conditions, so that long-term 
chronic suppressive antibiotic therapy (LTCSAT) remains the 
only viable treatment option. We here report a unique case of in-
travenous LTCSAT with dalbavancin, a long-acting lipopeptide 
antibiotic, in a patient who could not receive oral therapy [2].
CASE REPORT
A 78-year-old man presented to the emergency department 
for fever lasting 1 month. His medical history included benign 
prostatic hyperplasia, bowel diverticular disease and parkin-
sonism. Seven months before, he underwent aortic valve and 
tubular ascending aorta replacement by bioprosthetic devices 
(MagnaEase n.25 and HemaBridge n.10) due to severe aortic 
valve regurgitation and ascending aorta aneurysm.
On admission, high-resolution computed tomography re-
vealed a bleb of the ascending aorta posterior wall; additionally, 
hypodense areas, consistent with ischemic lesions, were de-
tected in the right kidney and spleen. Empiric antibiotic therapy 
with intravenous (i.v.) piperacillin-tazobactam (4.5 g TID) and 
i.v. daptomycin (500  mg/d) was started. A  transesophageal 
echocardiogram (TEE) displayed 2 vegetations (maximum di-
ameter 14 × 11 mm) on aortic cusps and a periprosthetic ab-
scess, whereas oxacillin-resistant Staphylococcus epidermidis 
(vancomycin minimal inhibitory concentration [MIC] 1  μg/
mL, daptomycin MIC 0.5 μg/mL, rifampicin ≤0.03 μg/mL) and 
highly penicillin-susceptible Streptococcus mitis (MIC 0.006 μg/
mL) were isolated from multiple blood cultures. IE was diag-
nosed, and targeted therapy with ceftriaxone 2 g BID, 10 mg/kg 
daptomycin, and 600 mg/d rifampicin was started, with prompt 
clearance of  bacteremia, although rifampin was stopped after 
2  days for poor tolerance. Poor clinical conditions and high 
perioperative risk (EuroSCOREII: 39.07%) were considered 
contraindications for immediate surgery. Thus, after 7 weeks, 
initial antimicrobial therapy was discontinued, and the patient 
was discharged after administration of 1500 mg i.v. dalbavancin 
(DBV). In vitro DBV susceptibility against the S.  epidermidis 
isolate was not available, so vancomycin susceptibility has been 
taken into account as a surrogate marker of DBV activity [3].
As reported in Table 1, DBV therapy was scheduled according 
to serum bactericidal activity (SBA) titers that were measured 
according to Leighton et  al. [4] and performed immediately 
before each DBV dose. In particular, after day 42 of therapy, it 
was decided to administer DBV whenever SBA titers ≤1:8 were 
detected; these circumstances accounted for SBA titers previ-
ously reported as resulting in bacteriological cure in infective 
endocarditis [5]. DBV concentrations have been assessed using 
a liquid chromatography–mass spectrometry method [6] at 3 
treatment time points: days 63, 112, and 133 (Table 1). Overall, 
our patient received 5 i.v. doses of 1500 mg of DBV, scheduled 
as shown in Table 1 (days 1, 7, 42, 112, 189).
While on LTCSAT, clinical conditions improved, with pro-
gressive disappearance of the 2 vegetative lesions on TEE scans 
(both originally <10  mm in diameter). On day 42 of DBV 
LTCSAT, a positron-emission tomography/computed tomog-
raphy (PET/CT) showed a 9-mm leak at the caudal anasto-
mosis of the aortic tube surrounded by an area of focal uptake, 
suggesting some residual infection. A  follow-up PET/CT 
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performed on day 140 of DBV LTCSAT showed both reduction 
of the leak lesion (4-mm diameter) and of the focal uptake. No 
alterations of renal, liver, and hemathopoiesis functions were 
observed throughout the period of DBV LTCSAT. Currently, 
the patient is recovered and asymptomatic, and he refuses eval-
uation for surgery.
DISCUSSION
In our case, the 7-week daptomycin plus ceftriaxone regimen 
without valve replacement could not be a successful therapy for 
our inoperable case of MRCoNS PVE. The high risk of recur-
rence was also suggested by alterations detected at follow-up 
PET/CT scans. As a matter of fact, this diagnostic tool is not 
also validated to monitor the clinical course of PVE; however, as 
some preliminary reports seem to suggest, we hypothesized that 
it could be of some help to confirm persistence of infection once 
inflammatory markers and TEE scans became negative [7, 8].
In our case, LTCSAT seemed advisable [9], possibly allowing 
a progressive clinical improvement with reduction of periopera-
tive mortality risk. To this end, oral options might have been 
linezolid or fusidic acid plus rifampicin. However, fusidic acid 
is not available in Italy, rifampicin was not tolerated by the pa-
tient, and linezolid has several side effects that contraindicate 
long-term therapy [10]. In this scenario, an i.v. treatment with 
DBV, a novel lipoglycopeptide with excellent antistaphylococcal 
activity and a half-life of approximately 346 hours, seemed an at-
tractive option [2–11]. Even though approved only for therapy of 
gram-positive acute bacterial skin and skin structure infections 
[11], in real-life practice DBV has been satisfactorily used also in 
gram-positive IE treatment [12], and a schedule of 2 i.v. doses of 
1500 mg 1 week apart has been recently validated for osteomye-
litis treatment, providing plasma and bone tissue exposure above 
the MIC 99.9 of 0.12 ug/mL for S. aureus for 8 weeks [13].
In conclusion, notwithstanding the uncertainty surrounding 
the appropriate target to redose DBV and the overall lack of 
clear contemporary data supporting the use of SBA titers as a 
surrogate for traditional PKPD to guide DBV dosing, an SBA-
monitored DBV LTCSAT allowed in our case not only sup-
pression of methicillin-resistant S.  epidermidis PVE, but also 
confinement of the infection to a small area adjacent to the 
anastomosis leak. Further investigations are required to as-
sess the real efficacy of this therapeutic approach to inoperable 
gram-positive PVEs.
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